KIF11
Kinesin-like protein KIF11
As of the edition of 20 October 2026, KIF11 (kinesin-like protein KIF11, UniProt P52732) has 4 drugs tested at it and 6 companies on the list, 6 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P52732
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 62
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Digestive system
- Registered trials of its drugs
- 37
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 3 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ispinesib | Stopped | Phase 2 | none listed |
| Filanesib | Went quiet | Phase 2 | none listed |
| Litronesib | Went quiet | Phase 2 | none listed |
| AZD-4877 | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| GSK | Route A |
| Eli Lilly | Route A |
| AstraZeneca | Route A |
The other 3 companies at KIF11
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at KIF11, ranked, with the facts behind eachRequest access. Nothing is shown until you do.